Part

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Retrieved on: 
Saturday, December 3, 2022

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”), and (ii) 974,000 units of the Company (“Units”) at a price of $1.25 per Unit (the “Unit Offering”), for aggregate gross proceeds of $2,049,334.

Key Points: 
  • Each Unit is comprised of one common share in the capital of the Company (a Share) and one common share purchase warrant (a Warrant).
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
  • Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.
  • Bright Minds drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

B. Braun's Space® Infusion Pump Systems Earn UL 2900-2-1 Certification

Retrieved on: 
Thursday, December 1, 2022

BETHLEHEM, Pa., Dec. 1, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the wireless devices of the Space Infusion Pump System* earned certification to UL 2900-2-1** through UL Cybersecurity Assurance Program (UL CAP). The UL 2900-2-1 standard is published as a U.S. national consensus standard by the American National Standards Institute (ANSI) and a recognized consensus standard by the U.S. Food and Drug Administration (FDA) supporting their pre- and post-market cybersecurity guidance.

Key Points: 
  • BETHLEHEM, Pa., Dec. 1, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the wireless devices of the Space Infusion Pump System* earned certification to UL 2900-2-1** through UL Cybersecurity Assurance Program (UL CAP).
  • The technical experts at UL Solutions explored all facets of the UL 2900-2-1 Standard requirements in their evaluation of the Space Infusion Pump Systems for CAP certification.
  • In addition to receiving certification to the UL 2900-2-1 Standard, Perfusor Syringe Pump,within B. Braun's Space Infusion Pump Systems platform, is the first in the industry with medical ground and/or air transport in the FDA cleared indications for use.
  • * Space Infusion Pump System includes the Wireless Infusomat 8713051U, SpaceStation with SpaceCom 8713142U, and Perfusor 8713031U.

PHOENIX HYDROGEN HUB LLC PROJECT INVITED INTO PHASE II OF U.S. DEPARTMENT OF ENERGY $1.3 BILLION LOAN APPLICATION PROCESS

Retrieved on: 
Thursday, December 1, 2022

PHOENIX, Dec.1, 2022 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, today announced that the Department of Energy Loan Program Office (LPO) has invited its Phoenix Hydrogen Hub LLC project loan application into Part II of its application process.

Key Points: 
  • PHOENIX, Dec.1, 2022 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, today announced that the Department of Energy Loan Program Office (LPO) has invited its Phoenix Hydrogen Hub LLC project loan application into Part II of its application process.
  • The project loan application was submitted on May 26, 2022 and has now progressed through the Part I review.
  • The application process is wholly dependent on the results of the Department of Energy (DOE) review and evaluation of a Part II Application, and DOE's determination whether to proceed.
  • The application for a loan guarantee under the Innovative Clean Energy projects solicitation could amount to about $1.3 billion.

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

Retrieved on: 
Thursday, December 1, 2022

WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET.

Key Points: 
  • WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET.
  • To join the webcast, please visit this link , or the Events & Presentations page of the Investors section on the Companys website at www.kymeratx.com .
  • Kymera Therapeutics (Nasdaq: KYMR) is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics.
  • For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Retrieved on: 
Wednesday, November 30, 2022

There is an offering document (the Offering Document) related to the Offering that can be accessed under the Companys profile at www.sedar.com and on the Companys website at https://revivethera.com .

Key Points: 
  • There is an offering document (the Offering Document) related to the Offering that can be accessed under the Companys profile at www.sedar.com and on the Companys website at https://revivethera.com .
  • As disclosed in the Offering Document, the company intends to use the net proceeds for general working capital purposes and clinical development.
  • The Offering is anticipated to close on or about December 14, 2022, or such later date as the Company may determine.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Mopar Shows Off New Ugly Holiday Sweater Just in Time for Holiday Season

Retrieved on: 
Wednesday, November 30, 2022

From branded apparel and lifestyle products to holiday-themed items, these holiday gift ideas will put a smile on the face of every Mopar fan.

Key Points: 
  • From branded apparel and lifestyle products to holiday-themed items, these holiday gift ideas will put a smile on the face of every Mopar fan.
  • Celebrate the holiday season with a traditional ugly sweater that fully embraces the performance-car theme.
  • This medium-weight knit sweater features Mopar logos integrated into a custom graphic design
    Match the ugly holiday sweater with a Mopar holiday two-pair pack of socks.
  • One roll will wrap approximately nine medium- size gifts
    Transporting holiday beverages is easy with the Mopar stainless-steel, double-wall construction drinkware set.

Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

Retrieved on: 
Wednesday, November 30, 2022

TARRYTOWN, N.Y., Nov. 30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023.

Key Points: 
  • HoFH is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is the most severe form of familial hypercholesterolemia (FH).
  • The sBLA is supported by data from a three-part trial evaluating Evkeeza in children aged 5 to 11 years with HoFH.
  • The trial met its primary endpoint, showing children who added Evkeeza to other lipid-lowering therapies reduced their LDL-C by 48% at week 24 on average.
  • Part A (n=6) was a Phase 1b trial designed to assess the pharmacokinetics (PK), safety and tolerability of Evkeeza.

AbraSilver Announces $8 Million "Bought Deal" Private Placement

Retrieved on: 
Tuesday, November 29, 2022

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- AbraSilver Resource Corp. ("AbraSilver" or the "Company") (TSXV: ABRA; OTCQX: ABBRF) is pleased to announce that it has entered into an agreement with Eight Capital, as lead underwriter and bookrunner, and on behalf of a syndicate of underwriters (collectively, the "Underwriters"), in connection with a "bought deal" private placement financing of 21,622,000 units of the Company (the "Units") at a price of $0.37 per Unit (the "Issue Price"), for aggregate gross proceeds of $8,000,140 (the "Offering").

Key Points: 
  • AbraSilver is an advanced-stage exploration company focused on rapidly advancing its 100%-owned Diablillos silver-gold project in the mining-friendly Salta province of Argentina.
  • In addition, AbraSilver owns a portfolio of earlier-stage copper-gold projects including the La Coipita copper-gold project in the San Juan province of Argentina.
  • AbraSilver is listed on the TSX-V under the symbol ABRA and in the U.S. under the symbol ABBRF.
  • No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

RevoluGROUP Canada Inc. Extends Equity Investment Talks Term Sheet Period Until December 8th 2022 Midnight

Retrieved on: 
Tuesday, November 29, 2022

The Acquirers and the Company have approved a one-time extension of the term sheet's maximum closing date and the exclusivity term, which now ends at midnight on December 8th, 2022.

Key Points: 
  • The Acquirers and the Company have approved a one-time extension of the term sheet's maximum closing date and the exclusivity term, which now ends at midnight on December 8th, 2022.
  • Firstly, the parties concluded perhaps the most complicated Documentary Due Diligence phase as per the news release dated November 7 th , 2022 .
  • Secondly, in continued good faith, the parties signed the Mutual Business Development Strategy addendum on November 25 th , 2022 .
  • Therefore, the parties have approved the present Term Sheet Period and Exclusivity Extension to permit appropriate time for this crucial conclusive phase in the talks.

Take Control of Cloud Costs and Maximize Cloud Benefits: Aptum Cloud Impact Study

Retrieved on: 
Tuesday, November 29, 2022

Aptum , a hybrid multi-cloud managed service provider, has announced Part 3 of its annual Cloud Impact Study 2022, titled Taking Control of Cloud Costs .

Key Points: 
  • Aptum , a hybrid multi-cloud managed service provider, has announced Part 3 of its annual Cloud Impact Study 2022, titled Taking Control of Cloud Costs .
  • Runaway cloud costs When businesses do not configure the cloud to scale up and down effectively, they often consume more resources than predicted.
  • Unforeseen costs associated with the cloud can be a challenge for many businesses that lack a comprehensive cloud strategy.
  • To see the full findings from part three of Aptums Cloud Impact Study 2022, Taking Control of Cloud Costs, download the report here: https://aptum.com/cloud-hub/2022-cis-part-3/ .